Literature DB >> 33752417

Male breast cancer with ureteral metastasis: a case report.

Yanbo Chen1, Jiannan Wu1, Tingting Hu1, Juanjuan Wang2, Fengxi Su1.   

Abstract

Breast cancer is rare in men and there is no report of male breast cancer (MBC) with ureteral metastasis. In this study, we report the first case of MBC with ureteral metastasis. A 60-year-old man was diagnosed with triple negative breast cancer (TNBC) with local lymph nodes metastasis (TNM stage: T4N3M0). After surgery, chemotherapy and radiotherapy he was diagnosed with ureter metastasis because of hematuria. This patient took a Precitype gene test (immune index and PAM50) after several lines of treatment and the result indicated that this was a Luminal A subtype case as well as HER-2 mRNA positive, which was quite different from his immunohistochemical staining. Because of his poor condition and he could not tolerate chemotherapy, we adjusted his therapeutic regimen with endocrine therapy and anti-HER-2 therapy according to the gene expression analysis with the informed consent of the patient and his families. However, it seemed that there was no obvious efficacy and he passed away five months later. In our opinion, MBC patients with urinary symptoms should be considered for the possibility of metastasis although urinary metastasis in breast cancer is rare. We still need more research about gene expression analysis and more evidence of treatment recommendations for MBC.

Entities:  

Keywords:  Male breast cancer (MBC); case report; gene expression analysis; ureteral metastasis

Year:  2021        PMID: 33752417     DOI: 10.21037/apm-20-2374

Source DB:  PubMed          Journal:  Ann Palliat Med        ISSN: 2224-5820


  1 in total

1.  Diagnostic and Therapeutic Challenges in a Patient with Ureteral Metastases from a Triple Negative Breast Cancer.

Authors:  Georgia Saranti; Vasiliki Zolota; Christina Kalogeropoulou; Nikolaos Papathanasiou; Theodora Katsila; Konstantina Kitsou; Ilias Haliassos; Dimitrios Kardamakis
Journal:  Curr Oncol       Date:  2022-07-07       Impact factor: 3.109

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.